Systematic review of longitudinal studies on chemotherapy-associated subjective cognitive impairment in cancer patients
- PMID: 32017297
- DOI: 10.1002/pon.5339
Systematic review of longitudinal studies on chemotherapy-associated subjective cognitive impairment in cancer patients
Abstract
Objectives: This systematic review of longitudinal studies, assessing subjective cognitive impairment (SCI) reported by adult cancer patients, aimed to summarize evidence on the impact of chemotherapy on SCI, identify moderators of SCI, and evaluate methodological issues.
Methods: Data accrued from Pubmed, EMBASE, CINAHL, PsychInfo, and the Cochrane library. Inclusion criteria were original studies, an exclusively adult sample, valid and reliable subjective cognitive measures, and at least one baseline data point prior to and another after the initiation of chemotherapy. Data were collected on the sample composition, data-collection time points, outcome measures, statistical analysis, and major findings (ie, longitudinal changes in prevalence, severity, and associated factors).
Results: Forty articles published between 2004 and 2019 were retained: 21 examined chemotherapy-treated patients only, and 19 employed control groups. Findings were mixed, with slightly more studies supporting the impact of chemotherapy on SCI. SCI tended to be more prevalent and severe after initiating chemotherapy, compared with patients' own baseline and controls not treated with chemotherapy. Impact appeared to be acute and more likely limited to subsamples. Most studies examining non-breast-cancer samples reported the lack or limited impact of chemotherapy on SCI. The most consistent moderators were depression and fatigue. Methodological issues regarding sampling design, measurement, and statistical analysis were discussed.
Conclusion: More rigorously designed longitudinal studies would clarify direct and indirect effects of chemotherapy on SCI.
Keywords: anxiety; cancer; cognitive function; cognitive impairment; depression; fatigue; oncology; systematic review.
© 2020 John Wiley & Sons, Ltd.
References
REFERENCES
-
- Joly F, Giffard B, Rigal O, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force Symposium and update since 2012. J Pain Symptom Manage. 2015;50:830-841. https://doi.org/10.1016/j.painsymman.2015.06.019.
-
- Pullens MJ, De Vries J, Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology. 2010;19:1127-1138. https://doi.org/10.1002/pon.1673.
-
- Li M, Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci Biobehav Rev. 2018;92:304-317. https://doi.org/10.1016/j.neubiorev.2018.05.019.
-
- Ahles TA, Hurria A. New challenges in psycho-oncology research IV: cognition and cancer: conceptual and methodological issues and future directions. Psychooncology. 2018;27:3-9. https://doi.org/10.1002/pon.4564.
-
- Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65:123-138. https://doi.org/10.3322/caac.21258.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical